{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:17:58Z","timestamp":1789834678023,"version":"4.0.1"},"reference-count":32,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,7,15]]},"DOI":"10.2169\/internalmedicine.4503-20","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T22:06:22Z","timestamp":1594764382000},"page":"1705-1710","source":"Crossref","is-referenced-by-count":12,"title":["Lipoprotein (a) and the Risk of Chronic Kidney Disease in Hospitalized Japanese Patients"],"prefix":"10.2169","volume":"59","author":[{"given":"Hayato","family":"Tada","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yamagami","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Teramoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Takamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masa-aki","family":"Kawashiri","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Levey AS, Coresh J. Chronic kidney disease. Lancet 379: 165-180, 2012.","DOI":"10.1016\/S0140-6736(11)60178-5"},{"key":"2","unstructured":"2. Stevens PE, O&apos;Donoghue DJ, de Lusignan S, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 72: 92-99, 2007."},{"key":"3","unstructured":"3. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80: 572-586, 2011."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kent S, Schlackow I, Lozano-K\u00fchne J, et al.  What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. BMC Nephrol 16: 65, 2015.","DOI":"10.1186\/s12882-015-0054-0"},{"key":"5","unstructured":"5. Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 67: 728-741, 2016."},{"key":"6","unstructured":"6. National Kidney. Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60: 850-886, 2012."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135: 73-87, 2001.","DOI":"10.7326\/0003-4819-135-2-200107170-00007"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.","DOI":"10.1056\/NEJMoa011303"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.","DOI":"10.1056\/NEJMoa011161"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Marcovina SM, Koschinsky ML. Lipoprotein (a) as a risk factor for coronary artery disease. Am J Cardiol 82: 57U-66U, 1998.","DOI":"10.1016\/S0002-9149(98)00954-0"},{"key":"11","unstructured":"11. Anuurad E, Boffa MB, Koschinsky ML, Berglund L. Lipoprotein (a): a unique risk factor for cardiovascular disease. Clin Lab Med 26: 751-772, 2006."},{"key":"12","unstructured":"12. Hobbs HH, White AL. Lipoprotein (a): intrigues and insights. Curr Opin Lipidol 10: 225-236, 1999."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lin J, Reilly MP, Terembula K, Wilson FP. Plasma lipoprotein (a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria. PLoS One 9: e114397, 2014.","DOI":"10.1371\/journal.pone.0114397"},{"key":"14","unstructured":"14. Kollerits B, Drechsler C, Krane V, et al. Lipoprotein (a) concentrations, apolipoprotein (a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study. Nephrol Dial Transplant 31: 1901-1908, 2016."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yun JS, Ahn YB, Song KH, et al. Lipoprotein (a) predicts a new onset of chronic kidney disease in people with Type 2 diabetes mellitus. Diabet Med 33: 639-643, 2016.","DOI":"10.1111\/dme.12862"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 89: 59-67, 1991.","DOI":"10.1016\/0021-9150(91)90007-P"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein (a) and the risk of myocardial infarction. JAMA 270: 2195-2199, 1993.","DOI":"10.1001\/jama.270.18.2195"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Erqou S, Kaptoge S, Perry PL, et al.; Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302: 412-423, 2009.","DOI":"10.1001\/jama.2009.1063"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Emdin CA, Khera AV, Natarajan P, et al. Phenotypic characterization of genetically lowered human lipoprotein (a) levels. J Am Coll Cardiol 68: 2761-2772, 2016.","DOI":"10.1016\/j.jacc.2016.10.033"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein (a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Circulation 129: 635-642, 2014.","DOI":"10.1161\/CIRCULATIONAHA.113.004406"},{"key":"21","unstructured":"21. O&apos;Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein (a), PCSK9 inhibition and cardiovascular risk: insights from the FOURIER Trial. Circulation 139: 1483-1492, 2019."},{"key":"22","unstructured":"22. Tada H, Kawashiri MA, Takata M, et al. Infantile cases of sitosterolemia with novel mutations in the ABCG5 gene: extreme hypercholesterolemia is exacerbated by breastfeeding. JIMD Rep 21: 115-122, 2015."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Wu JH, Kao JT, Wen MS, Wu D. Coronary artery disease risk predicted by plasma concentrations of high-density lipoprotein cholesterol, apolipoprotein AI, apolipoprotein B, and lipoprotein (a) in a general Chinese population. Clin Chem 39: 209-212, 1993.","DOI":"10.1093\/clinchem\/39.2.209"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Seino Y, Nanjo K, Tajima N, et al.; Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 1: 212-228, 2010.","DOI":"10.1111\/j.2040-1124.2010.00074.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidey Dis 53: 982-992, 2009.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Berg K. A new serum type system in man-the LP system. Acta Pathol Microbiol Scand  59: 369-382, 1963.","DOI":"10.1111\/j.1699-0463.1963.tb01808.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kronenberg F. Causes and consequences of lipoprotein (a) abnormalities in kidney disease. Clin Exp Nephrol 18: 234-237, 2014.","DOI":"10.1007\/s10157-013-0875-8"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ikewaki K. <i>In vivo<\/i> kinetic studies to further understand pathogenesis of abnormal lipoprotein metabolism in chronic kidney disease. Clin Exp Nephrol 18: 261-264, 2014.","DOI":"10.1007\/s10157-013-0881-x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Hervio L, Girard-Globa A, Durlach V, Angl\u00e9s-Cano E. The antifibrinolytic effect of lipoprotein (a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein (a) isoforms and their affinity for fibrin. Eur J Clin Invest 26: 411-417, 1996.","DOI":"10.1046\/j.1365-2362.1996.156288.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Konishi H, Miyauchi K, Tsuboi S, et al. Plasma lipoprotein (a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention. Int J Cardiol 205: 50-53, 2016.","DOI":"10.1016\/j.ijcard.2015.12.007"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Xu N, Tang XF, Yao Y, et al. Association of plasma lipoprotein (a) with long-term adverse events in patients with chronic kidney disease who underwent percutaneous coronary intervention. Am J Cardiol 122: 2043-2048, 2018.","DOI":"10.1016\/j.amjcard.2018.04.058"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein (a). Clin Chem 46: 1956-1967, 2000.","DOI":"10.1093\/clinchem\/46.12.1956"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/14\/59_4503-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T03:28:53Z","timestamp":1595042933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/14\/59_4503-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":32,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4503-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]}}}